Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 15, 2023

Trastuzumab Deruxtecan in Patients With HER2+ Advanced Gastric or GEJ Cancer Who Progressed on or After a Trastuzumab-Containing Regimen

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
Lancet Oncol 2023 Jun 14;[EPub Ahead of Print], E Van Cutsem, M di Bartolomeo, E Smyth, I Chau, H Park, S Siena, S Lonardi, ZA Wainberg, J Ajani, J Chao, Y Janjigian, A Qin, J Singh, F Barlaskar, Y Kawaguchi, G Ku

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading